Zoledronate (CGP 42'446), a bisphosphonate, protects against metaphyseal intracortical defects in experimental inflammatory arthritis

Journal of Orthopaedic Research

Volumn 15, Issue 6, 1997, Pages 858-861

  Pysklywec, M W ^a   Moran, E L ^a   Bogoch, E R ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTER AIDED DIAGNOSIS; DEFECTS; DRUG PRODUCTS; IMAGE ANALYSIS; JOINTS (ANATOMY); MEDICAL IMAGING; PHOSPHORUS COMPOUNDS;

BISPHOSPHONATE; INFLAMMATORY ARTHRITIS;

BONE;

BISPHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE DEFECT; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFICACY; IMAGE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RABBIT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031277793     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.1100150610     Document Type: Article

References (19)

1. 1 Åkesson K, Önsten I, Obrant KJ: Periarticular bone in rheumatoid arthritis versus arthrosis. Acta Orthop Scand 65: 135–138, 1994
2. 2 Bellingham CM, Lee JM, Moran EL, Bogoch ER: Bisphosphonate (pamidronate/APD) prevents arthritis‐induced loss of fracture toughness in the rabbit femoral diaphysis. J Orthop Res 13: 876–880, 1995
3. 3 Bogoch ER, Gschwend N, Bogoch B, Rahn B, Perren S: Juxta‐articular bone loss in experimental inflammatory arthritis. J Orthop Res 6: 648–656, 1988
4. 4 Bogoch ER, Hastings D, Gross A, Gschwend N: Supracondylar fractures of the femur adjacent to resurfacing and Macintosh arthroplasties of the knee in patients with rheumatoid arthritis. Clin Orthop 229: 213–220, 1988
5. 5 Bogoch ER, Gschwend N, Bogoch B, Rahn B, Perren S: Changes in the metaphysis and diaphysis of the femur proximal to the knee in rabbits with experimentally induced inflammatory arthritis. Arthritis Rheum 32: 617–624, 1989
6. 6 Bogoch ER, Roberts E, Moran EL, Fornasier V: Pamidronate (APD) prevents rapid bone remodeling and rapid bone loss in ElA. Orthop Trans 19: 1110, 1996
7. 7 Bogoch ER, Moran EL, Roberts EM, Fornasier VL: Bisphosphonate CGP 42'446 reduces cartilage degeneration in experimental inflammatory arthritis (EIA) via tidemark protection. Orthop Trans 20: 968–69, 1996–1997
8. 8 Brooks DB, Burstein AH, Frankel VH: The biomechanics of torsional fractures: the stress concentration effect of a drill hole. J Bone Joint Surg [Am]. 52: 507–514, 1970
9. 9 Currev JD: Stress concentrations in bone. J Micro Sci 103: 111–133, 1962
10. 10 Fleisch H: Bisphosphonates: history and experimental basis. Bone 8 (Suppl 1): S23–S28, 1987
11. 11 Grynpas MD, Lieberman IH, Bogoch ER, Pritzker KPH: The effect of rheumatoid arthritis on subchondral bone. Orthop Trans 17: 365–366, 1993
12. 12 Hooyman JR, Melton LJ III, Nelson AM, O'Fallon WM, Riggs BL: Fractures after rheumatoid arthritis: a population‐based study. Arthritis Rheum 27: 1353–1361, 1984
13. 13 Kröger H, Arnala I, Rehnberg V, Hämäläinen M, Alhava E: Histomorphometry of periarticular bone in rheumatoid arthritis. Ann Chir Gynaecol 83: 56–62, 1994
14. 14 Martin AD, Silverthorn KG, Houston CS, Bernhardson S, Wajda A, Roos LL: The incidence of fracture of the proximal femur in two million Canadians from 1972 to 1984: projections for Canada in the year 2006. Clin Orthop 266: 111–118, 1991
15. 15 Martin RB: Porosity and specific surface of bone. Crit Rev Biomed Eng. l0: 179–222, 1984
16. 16 Pysklywec MW, Bogoch ER, Moran EL, Fornasier VL: Altered pore characteristics and geometry in diaphyseal cortical bone affected by experimental inflammatory arthritis. J Orthop Rheumatol 9: 150–156, 1996
17. 17 Spector TD, Hall GM, McCloskey EV, Kanis JA: Risk of vertebral fracture in women with rheumatoid arthritis. Br Med J 306: 558, 1993
18. 18 Takashima T, Kawai K, Hirohata K, Miki A, Mizoguti H, Cooke TDV: Inflammatory cell changes in Haversian canals: a possible cause of osteoporosis in rheumatoid arthritis. J Bone Joint Surg [Br] 71: 671–676, 1989
19. 19 Watts NB: Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin N Am 20: 717–734, 1994